Pharmaceutical compounds
US11154539B2 · kind B2 · utility
2Cited by
4References
8Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Oct 20, 2017 |
| Grant date | Oct 26, 2021 |
| Priority date | — |
| Expiry date | Oct 20, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/675
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a compound for use in the treatment of T-Cell Acute Lymphoblastic Leukaemia (T-ALL), the compound having the formula (1): or being a pharmaceutically acceptable salt thereof; wherein: n is 0, 1 or 2; Ar1 is selected from an optionally substituted phenyl, pyridyl, thienyl and furanyl; Q1 is selected from C(═O), S(═O) and SO2; A is absent or is NR2; R1 is selected from:
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.